Clinical Endocrinology & Drug Safety Engine

Interactive Diabetology & Polypharmacy Suite

Codifies ADA 2024 Standards of Care (Sec 6, 7 & 9), KDIGO 2022, RSSDI 2022, and ATTD Consensus

Polypharmacy & AKI Guard

TRIPLE WHAMMY AUDIT

1-Click Clinical Presets:

Triple Whammy AKI Beta-Blocker + Insulin Statin + Gemfibrozil Safe Regimen

Current Medication Regimen (One per line or comma-separated):

CRITICAL DRUG INTERACTION DETECTED

'Triple Whammy' AKI Hazard: Co-prescription of [Telmisartan ARB] + [Dapagliflozin SGLT2i] + [Diclofenac NSAID]. Efferent vasodilation + afferent vasoconstriction + volume loss causes acute loss of intraglomerular pressure and ischemic tubular necrosis. Discontinue NSAID immediately; switch to Paracetamol.

Dynamic Insulin & Bolus

ICR (500) · ISF (1800)

Patient Weight (kg)

Diabetes Type

Known Total Daily Dose (TDD Units) (Optional)

Current BG

Target BG

Meal Carbs (g)

Total Daily Dose (TDD) 42.0 Units

Basal Insulin (50%) 21.0 Units OD

Carb Ratio (500/TDD) 1 U : 11.9 g

Sensitivity (1800/TDD) 1 U : 42.9 mg/dL

Recommended Meal Bolus 5.0 U (Carb) + 1.6 U (Correction)

6.6 Units

CGM AGP Analyzer

TIR · TBR · %CV · GMI

Time In Range (TIR 70–180 %)

Mean Glucose (mg/dL)

TBR Level 1 (54–69 mg/dL %)

TBR Level 2 (< 54 mg/dL %)

Glycemic Var (%CV)

Older / Frail

Glucose Management Indicator (GMI) 7.0%

Time in Range (70–180 mg/dL): 74% GOAL MET (>70%)

Time Below Range (<70 mg/dL): 2.9% SAFE (<4%)

Glycemic Variability (%CV): 32.4% STABLE (<=36%)